Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transl Stroke Res ; 13(2): 265-275, 2022 04.
Article in English | MEDLINE | ID: mdl-34491543

ABSTRACT

Subarachnoid haemorrhage (SAH) is associated with long-term disability, serious reduction in quality of life and significant mortality. Early brain injury (EBI) refers to the pathological changes in cerebral metabolism and blood flow that happen in the first few days after ictus and may lead on to delayed cerebral ischaemia (DCI). A disruption of the nitric oxide (NO) pathway is hypothesised as a key mechanism underlying EBI. A decrease in the alpha-delta power ratio (ADR) of the electroencephalogram has been related to cerebral ischaemia. In an experimental medicine study, we tested the hypothesis that intravenous sodium nitrite, an NO donor, would lead to increases in ADR. We studied 33 patients with acute aneurysmal SAH in the EBI phase. Participants were randomised to either sodium nitrite or saline infusion for 1 h. EEG measurements were taken before the start of and during the infusion. Twenty-eight patients did not develop DCI and five patients developed DCI. In the patients who did not develop DCI, we found an increase in ADR during sodium nitrite versus saline infusion. In the five patients who developed DCI, we did not observe a consistent pattern of ADR changes. We suggest that ADR power changes in response to nitrite infusion reflect a NO-mediated reduction in cerebral ischaemia and increase in perfusion, adding further evidence to the role of the NO pathway in EBI after SAH. Our findings provide the basis for future clinical trials employing NO donors after SAH.


Subject(s)
Brain Injuries , Brain Ischemia , Subarachnoid Hemorrhage , Biomarkers , Brain Injuries/complications , Brain Ischemia/complications , Cerebral Infarction/complications , Electroencephalography , Humans , Quality of Life , Sodium Nitrite/therapeutic use
2.
J Cereb Blood Flow Metab ; 39(2): 285-301, 2019 02.
Article in English | MEDLINE | ID: mdl-28857714

ABSTRACT

Acute cerebral hypoxia causes rapid calcium shifts leading to neuronal damage and death. Calcium channel antagonists improve outcomes in some clinical conditions, but mechanisms remain unclear. In 18 healthy participants we: (i) quantified with multiparametric MRI the effect of hypoxia on the thalamus, a region particularly sensitive to hypoxia, and on the whole brain in general; (ii) investigated how calcium channel antagonism with the drug nimodipine affects the brain response to hypoxia. Hypoxia resulted in a significant decrease in apparent diffusion coefficient (ADC), a measure particularly sensitive to cell swelling, in a widespread network of regions across the brain, and the thalamus in particular. In hypoxia, nimodipine significantly increased ADC in the same brain regions, normalizing ADC towards normoxia baseline. There was positive correlation between blood nimodipine levels and ADC change. In the thalamus, there was a significant decrease in the amplitude of low frequency fluctuations (ALFF) in resting state functional MRI and an apparent increase of grey matter volume in hypoxia, with the ALFF partially normalized towards normoxia baseline with nimodipine. This study provides further evidence that the brain response to acute hypoxia is mediated by calcium, and importantly that manipulation of intracellular calcium flux following hypoxia may reduce cerebral cytotoxic oedema.


Subject(s)
Brain Edema , Calcium Channel Blockers/administration & dosage , Hypoxia, Brain , Magnetic Resonance Imaging , Nimodipine/administration & dosage , Thalamus , Adult , Brain Edema/diagnostic imaging , Brain Edema/drug therapy , Brain Edema/etiology , Brain Edema/metabolism , Calcium/metabolism , Calcium Signaling/drug effects , Female , Humans , Hypoxia, Brain/complications , Hypoxia, Brain/diagnostic imaging , Hypoxia, Brain/drug therapy , Hypoxia, Brain/metabolism , Male , Thalamus/diagnostic imaging , Thalamus/metabolism
3.
Hum Mutat ; 30(7): 1082-92, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19388127

ABSTRACT

Genomic microarrays have been implemented in the diagnosis of patients with unexplained mental retardation. This method, although revolutionizing cytogenetics, is still limited to the detection of rare de novo copy number variants (CNVs). Genome-wide single nucleotide polymorphism (SNP) microarrays provide high-resolution genotype as well as CNV information in a single experiment. We hypothesize that the widespread use of these microarray platforms can be exploited to greatly improve our understanding of the genetic causes of mental retardation and many other common disorders, while already providing a robust platform for routine diagnostics. Here we report a detailed validation of Affymetrix 500k SNP microarrays for the detection of CNVs associated to mental retardation. After this validation we applied the same platform in a multicenter study to test a total of 120 patients with unexplained mental retardation and their parents. Rare de novo CNVs were identified in 15% of cases, showing the importance of this approach in daily clinical practice. In addition, much more genomic variation was observed in these patients as well as their parents. We provide all of these data for the scientific community to jointly enhance our understanding of these genomic variants and their potential role in this common disorder.


Subject(s)
Intellectual Disability/genetics , Karyotyping , Polymorphism, Single Nucleotide , Gene Dosage , Genetic Variation , Heterozygote , Humans , Oligonucleotide Array Sequence Analysis , Reagent Kits, Diagnostic/standards , Uniparental Disomy
SELECTION OF CITATIONS
SEARCH DETAIL
...